F8 and hemophilia A: While there is currently a lack of consistency in the reporting of specific outcomes of interest, particularly with regard to AESIs, our analysis indicates that the reported experience of major surgery in people with hemophilia A without FVIII inhibitors on emicizumab is increasing.